<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708795</url>
  </required_header>
  <id_info>
    <org_study_id>SELECT</org_study_id>
    <nct_id>NCT04708795</nct_id>
  </id_info>
  <brief_title>Clinical Trial on Pharmacokinetic and Tolerability of AP701</brief_title>
  <official_title>Clinical Trial on Pharmacokinetic and Tolerability of AP701</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CannaXan GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CannaXan GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the uptake of AP701, a preparation from cannabis flowers, into&#xD;
      the bloodstream after in single administration in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetic parameters and tolerability of AP701 is studied over 30 hours after single&#xD;
      dose administration in healthy volunteers in a prospective and open-label manner at a single&#xD;
      study center.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2020</start_date>
  <completion_date type="Actual">March 7, 2021</completion_date>
  <primary_completion_date type="Actual">March 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of THC (area under the curve)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of THC measured 0 to 30 hours after application of investigational product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of THC (maximum observed drug concentration)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of THC measured 0 to 30 hours after application of investigational product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of THC (time to reach maximum drug concentration)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of THC measured 0 to 30 hours after application of investigational product</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of THC (area under the curve from timepoint zero to quantification limits)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of THC measured 0 to detection limits after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of THC (area under the curve from 0 to 24 hours)</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic outcome of THC measured 0 to 24 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of THC (last drug concentration above quantification limits)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of THC measured 0 to 30 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of THC (time of last drug concentration above quantification limits)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of THC measured 0 to 30 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of THC (half-life associated with the terminal slope)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of THC measured 0 to 30 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of 11-OH-THC (area under the curve)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of 11-OH-THC measured 0 to 30 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of 11-OH-THC (maximum observed drug concentration)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of 11-OH-THC measured 0 to 30 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of 11-OH-THC (time to reach maximum drug concentration)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of 11-OH-THC measured 0 to 30 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of 11-OH-THC (area under the curve from timepoint zero to quantification limits)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of 11-OH-THC measured 0 to 30 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of 11-OH-THC (area under the curve from 0 to 24 hours)</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic outcome of 11-OH-THC measured 0 to 24 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of 11-OH-THC (last drug concentration above quantification limits)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of 11-OH-THC measured 0 to 30 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of 11-OH-THC (time of last drug concentration above quantification limits)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of 11-OH-THC measured 0 to 30 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pharmacokinetic parameter of 11-OH-THC (half-life associated with the terminal slope)</measure>
    <time_frame>30 hours</time_frame>
    <description>Pharmacokinetic outcome of 11-OH-THC measured 0 to 30 hours after application of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>30 hours</time_frame>
    <description>Number and severity of adverse events (AE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pschotropic drug effects measured by questionnaire</measure>
    <time_frame>30 hours</time_frame>
    <description>Questionnaire comprising 17 questions on intoxication to be answered on numeric rating scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Pharmacokinetic</condition>
  <condition>Tolerability</condition>
  <condition>Safety</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AP701 single dose oromucosal application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP701</intervention_name>
    <description>Preparation of Cannabis flowers (Cannabis flos)</description>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent form&#xD;
&#xD;
          2. Male in the age of 35 - 60 year at study start&#xD;
&#xD;
          3. Body mass index of 18 to 30 kg/m2&#xD;
&#xD;
          4. Non-smoker, no use of any Tabaco products&#xD;
&#xD;
          5. Good general health status (Karnofsky Score = 100)&#xD;
&#xD;
          6. Current ECG without abnormal findings (i.a. QTcF &lt; 450 ms)&#xD;
&#xD;
          7. Physical examination, medical history without exclusionary findings&#xD;
&#xD;
          8. Pulse rate between 50 and 90 bpm&#xD;
&#xD;
          9. Blood pressure between systolic 90 - 140 mmHg, diastolic 50 - 90 mmHg&#xD;
&#xD;
         10. Lab values for liver function (ALT, AST, AP, Bilirubin total) within normal ranges&#xD;
&#xD;
         11. Lab values for renal function (S-Creatinine, eGFR) within normal range&#xD;
&#xD;
         12. Negative test result on HIV I, HIV II, hepatitis B cell surface antigen, hepatitis C&#xD;
             antibody&#xD;
&#xD;
         13. Negative test result of urine screening for Cannabis, alcohol, and substance abuse&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical history of hypersensitivity or intolerance to the investigational product or&#xD;
             its ingredients or to ingredients of similar chemical structure&#xD;
&#xD;
          2. Use of Cannabis products within the last 8 weeks&#xD;
&#xD;
          3. Use of opioids&#xD;
&#xD;
          4. Former or present dependency (e.g. to alcohol, medicinal products, drugs)&#xD;
&#xD;
          5. Participation in another clinical trial within the last four weeks prior to study&#xD;
             inclusion&#xD;
&#xD;
          6. Present, former, or family history of mental illnesses such as severe de pression,&#xD;
             psychosis, bipolar disorder, mania, obsessive compulsive disorder, and anxiety&#xD;
             disorder&#xD;
&#xD;
          7. Acute severe somatic disease (e.g. gastrointestinal diseases, influenza)&#xD;
&#xD;
          8. Body temperature ≥ 38 °C&#xD;
&#xD;
          9. Present cardiovascular, respiratory, diabetic, or cancer disease&#xD;
&#xD;
         10. Hepatitis or other liver and renal disease&#xD;
&#xD;
         11. Other diseases or conditions that do not allow the participant to assess the nature&#xD;
             and scope, and possible consequences of participating in this clinical trial&#xD;
&#xD;
         12. Indications that the participant is unlikely to comply with the study protocol (e.g.&#xD;
             lack of cooperation)&#xD;
&#xD;
         13. Taking any pharmaceutical products (including any medication interacting with&#xD;
             metabolism of THC, e.g. St. John's wort)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Lorenzl, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phase I Unit of CannaXan GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phase I Unit of CannaXan GmbH</name>
      <address>
        <city>Warngau</city>
        <state>Bavaria</state>
        <zip>D-83627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cannabis</keyword>
  <keyword>Cannabis based medicine</keyword>
  <keyword>THC</keyword>
  <keyword>Tetrahydrocannbinol</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

